GSK wins FDA approval for Hibsago to treat chronic hepatitis B
GSK•The FDA approved GSK’s Hibsago (bepirovirsen), licensed from Ionis Pharmaceuticals, for eligible adults with chronic hepatitis B alongside nucleos(t)ide analogue therapy. Ionis is eligible for additional regulatory and sales milestone payments and tiered royalties of 10% to 12% on net sales.
1. Approval and royalties
The FDA approved GSK’s Hibsago (bepirovirsen), which is licensed from Ionis Pharmaceuticals, for chronic hepatitis B in eligible adults alongside nucleos(t)ide analogue therapy. Ionis is eligible for additional regulatory and sales milestone payments, plus tiered royalties of 10% to 12% on net sales.
